Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial.

AIMS Naltrexone can be used to treat opioid dependence, but patients refuse to take it. Extended-release depot formulations may improve adherence, but long-term adherence rates to depot naltrexone are not known. This study determined long-term rates of adherence to depot naltrexone and whether employment-based reinforcement can improve adherence. DESIGN Participants who were inducted onto oral naltrexone were assigned randomly to contingency (n = 18) or prescription (n = 17) groups. Participants were offered six depot naltrexone injections and invited to work at the therapeutic workplace on week days for 26 weeks, where they earned stipends for participating in job skills training. Contingency participants were required to accept naltrexone injections to maintain workplace access and to maintain maximum pay. Prescription participants could work independently of whether they accepted injections. SETTING The therapeutic workplace, a model employment-based intervention for drug addiction and unemployment. PARTICIPANTS Opioid-dependent unemployed adults. MEASUREMENTS Depot naltrexone injections accepted and opiate-negative urine samples. FINDINGS Contingency participants accepted significantly more naltrexone injections than prescription participants (81% versus 42%), and were more likely to accept all injections (66% versus 35%). At monthly assessments (with missing urine samples imputed as positive), the groups provided similar percentages of samples negative for opiates (74% versus 62%) and for cocaine (56% versus 54%). Opiate-positive samples were more likely when samples were also positive for cocaine. CONCLUSIONS Employment-based reinforcement can maintain adherence to depot naltrexone. Future research should determine whether persistent cocaine use compromises naltrexone's effect on opiate use. Workplaces may be useful for promoting sustained adherence to depot naltrexone.

[1]  D. Segal Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) , 2010 .

[2]  K. Silverman,et al.  Employment-based abstinence reinforcement as a maintenance intervention for the treatment of cocaine dependence: a randomized controlled trial. , 2009, Addiction.

[3]  K. Silverman,et al.  Attendance rates in a workplace predict subsequent outcome of employment-based reinforcement of cocaine abstinence in methadone patients. , 2008, Journal of applied behavior analysis.

[4]  K. Silverman,et al.  Economic cost of the therapeutic workplace intervention added to methadone maintenance. , 2008, Journal of substance abuse treatment.

[5]  A. Brooks,et al.  Management of relapse in naltrexone maintenance for heroin dependence. , 2007, Drug and alcohol dependence.

[6]  J. Cairns,et al.  The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. , 2007, Health technology assessment.

[7]  Darlene E. Crone-Todd,et al.  A randomized trial of employment-based reinforcement of cocaine abstinence in injection drug users. , 2007, Journal of applied behavior analysis.

[8]  G. Hulse,et al.  Sustained-release naltrexone: novel treatment for opioid dependence , 2007, Expert opinion on investigational drugs.

[9]  T. Roberts,et al.  Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. , 2007, Health technology assessment.

[10]  C. O'brien,et al.  Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. , 2006, Archives of general psychiatry.

[11]  K. Silverman,et al.  A randomized trial of long-term reinforcement of cocaine abstinence in methadone-maintained patients who inject drugs. , 2004, Journal of consulting and clinical psychology.

[12]  D. Vlahov,et al.  Longitudinal patterns of drug injection behavior in the ALIVE Study cohort,1988-2000: description and determinants. , 2003, American journal of epidemiology.

[13]  V. Modesto-Lowe,et al.  Clinical uses of naltrexone: a review of the evidence. , 2002, Experimental and clinical psychopharmacology.

[14]  R. Sinha,et al.  Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement magnitude. , 2002, Experimental and clinical psychopharmacology.

[15]  H. Kleber,et al.  Depot naltrexone: long-lasting antagonism of the effects of heroin in humans , 2002, Psychopharmacology.

[16]  B. Rounsaville,et al.  Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. , 2001, Archives of general psychiatry.

[17]  Y I Hser,et al.  A 33-year follow-up of narcotics addicts. , 2001, Archives of general psychiatry.

[18]  A T McLellan,et al.  Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. , 2000, JAMA.

[19]  H. W. Clark,et al.  Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. , 2000, JAMA.

[20]  Gregory Camilli,et al.  Application of a Method of Estimating DIF for Polytomous Test Items , 1999 .

[21]  K. Schuh,et al.  Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans , 1999, Psychopharmacology.

[22]  K. Preston,et al.  Improvement in naltrexone treatment compliance with contingency management. , 1999, Drug and alcohol dependence.

[23]  W. H. Hall,et al.  Effective medical treatment of opiate addiction , 1998 .

[24]  Judith D. Singer,et al.  Using SAS PROC MIXED to Fit Multilevel Models, Hierarchical Models, and Individual Growth Models , 1998 .

[25]  K. Preston,et al.  Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. , 1996, The Journal of pharmacology and experimental therapeutics.

[26]  W. Compton,et al.  Comparing assessments of DSM-IV substance dependence disorders using CIDI-SAM and SCAN. , 1996, Drug and alcohol dependence.

[27]  P. Albert,et al.  Models for longitudinal data: a generalized estimating equation approach. , 1988, Biometrics.

[28]  F. J. Evans,et al.  New Data from the Addiction Severity Index Reliability and Validity in Three Centers , 1985, The Journal of nervous and mental disease.

[29]  G. Vaillant A 20-year follow-up of New York narcotic addicts. , 1973, Archives of general psychiatry.

[30]  D. Jasinski,et al.  Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. , 1973, Archives of general psychiatry.

[31]  K. Silverman Exploring the limits and utility of operant conditioning in the treatment of drug addiction , 2004, The Behavior analyst.

[32]  K. Silverman,et al.  A reinforcement-based therapeutic workplace for the treatment of drug abuse: three-year abstinence outcomes. , 2002, Experimental and clinical psychopharmacology.

[33]  A. Rosenblum,et al.  Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. , 2001, The Mount Sinai journal of medicine, New York.

[34]  K. Silverman,et al.  A reinforcement-based therapeutic workplace for the treatment of drug abuse: six-month abstinence outcomes. , 2001, Experimental and clinical psychopharmacology.

[35]  Charles B. Fleming,et al.  A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. , 1998, Addiction.

[36]  Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. , 1998, JAMA.

[37]  B. Rounsaville Can psychotherapy rescue naltrexone treatment of opioid addiction? , 1995, NIDA research monograph.

[38]  G. Woody,et al.  Preparations for AIDS vaccine trials. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors. , 1994, AIDS research and human retroviruses.

[39]  J. Mendelson,et al.  Operant analysis of human heroin self-administration and the effects of naltrexone. , 1981, The Journal of pharmacology and experimental therapeutics.

[40]  C. O'brien,et al.  Effects of contingent payment on compliance with a naltrexone regimen. , 1979, The American journal of drug and alcohol abuse.